Aripiprazole
In brief
- In our pharmacy you can buy aripiprazole without a prescription, with delivery across the United Kingdom in discreet, anonymous packaging and typical dispatch within 9â21 days.
- Aripiprazole is used to treat schizophrenia, bipolar I disorder (mania), as an adjunct for major depressive disorder and for irritability associated with autism; it acts as a partial agonist at dopamine D2 and serotonin 5âHT1A receptors and as an antagonist at 5âHT2A receptors.
- The usual oral dose for adults with schizophrenia is 10â15 mg once daily (up to 30 mg/day as a maximum); for acute mania 15 mg/day; as adjunct in depression 2â5 mg/day (up to 15 mg), and the longâacting injectable is typically 400 mg once monthly.
- Forms of administration include oral tablets (2, 5, 10, 15, 20, 30 mg), orally disintegrating tablets, oral solution (1 mg/mL) and a longâacting intramuscular depot injection (e.g. 300 mg or 400 mg vials / Abilify Maintena).
- Onset: some patients notice improvements in agitation or sleep within a few days, but meaningful antipsychotic effects often begin within 1â2 weeks and full benefit may take several weeks.
- Duration of action: when taken orally, aripiprazole is taken once daily and provides around 24 hours of effect; the monthly depot injection provides therapeutic levels for about one month.
- Do not drink alcohol while taking aripiprazole or limit alcohol intake, as alcohol can increase drowsiness, impair coordination and worsen side effects such as dizziness and orthostatic hypotension.
- The most common side effect is akathisia (motor restlessness); other frequent effects include insomnia, anxiety, headache, nausea, dizziness and somnolence.
- Would you like to try aripiprazole without a prescription?
Legal status and availability in the UK
In our online pharmacy, aripiprazole is available without a prescription, with discreet delivery to the United Kingdom in 9â21 days.
Basic aripiprazole information
- INN (international nonproprietary name): Aripiprazole
- Brand names available in the United Kingdom: Abilify, Abilify Maintena; generic aripiprazole
- ATC code: N05AX12
- Forms and strengths: tablets 2, 5, 10, 15, 20, 30 mg; oral solution 1 mg/mL; orally disintegrating tablets 10, 15 mg; longâacting depot injections 300 mg and 400 mg (Abilify Maintena)
- Manufacturers: generics by Mylan and Neuraxpharm; original brands by Otsuka (Abilify/Abilify Maintena)
- Registration status in the United Kingdom: Prescription-only medicine
- OTC / Rx classification: Prescriptionâonly (Rx)
Clinical effectiveness in the UK
How does aripiprazole perform in everyday NHS practice?
Aripiprazole is a common choice in firstâepisode and chronic schizophrenia.
Clinicians often select aripiprazole when weight gain and prolactin elevation are concerns, reflecting its comparatively favourable metabolic profile versus some alternatives.
Early treatment weeks commonly bring higher rates of akathisia and insomnia, so timely counselling and monitoring are essential.
For bipolar mania, typical regimens (15 mg/day, up to 30 mg) produce an antimanic effect within days to weeks.
UK clinicians balance the drugâs favourable metabolic profile against akathisia risk, and community pharmacists routinely counsel patients about early restlessness and sleep disturbance.
Indications and expanded uses (MHRAâapproved vs offâlabel)
What is aripiprazole licensed for, and where is it used offâlabel in the UK?
- Licensed indications
- Schizophrenia in adults and adolescents; manic episodes in bipolar I disorder.
- LAI indication
- Maintenance treatment in adults with monthly Abilify Maintena injections (300/400 mg).
- Common offâlabel uses
- Lowâdose adjunctive use in treatmentâresistant depression, irritability associated with autism spectrum disorder, augmentation in anxiety spectrum features, and tailored use where high metabolic risk from alternatives is a concern.
| Age/indication | Typical dose |
|---|---|
| Adult Schizophrenia | 10â15 mg/day (max 30 mg) |
| Adolescent Schizophrenia | Start 2 mg, titrate to ~10 mg as tolerated |
| Bipolar Mania (Adult) | 15 mg/day (max 30 mg) |
| Depression Adjunct (Adult) | 2â5 mg/day, up to 15 mg |
Risk governance: UK prescribers should document informed consent for offâlabel prescribing on NHS records and follow local Trust formularies.
Composition and UK brand landscape (active ingredients, generics)
What forms and brands of aripiprazole are available in the UK?
The active ingredient is aripiprazole (INN), ATC code N05AX12.
UK suppliers include generics from Mylan and Neuraxpharm, and branded products originally by Otsuka (Abilify and Abilify Maintena).
| Brand | Manufacturer | Common UK strengths/forms |
|---|---|---|
| Abilify | Otsuka / BristolâMyers Squibb | Tablets 2â30 mg; ODTs (select strengths) |
| Abilify Maintena | Otsuka | Depot injection 300 mg / 400 mg monthly |
| Generic Aripiprazole | Mylan, Neuraxpharm, Teva (supply varies) | Tablets 5, 10, 15, 30 mg |
Packaging commonly ranges from 10â to 100âtablet blisters for oral products, and singleâvial presentation for depot injections.
Contraindications and special precautions (highârisk groups)
Who needs particular caution with aripiprazole?
Absolute contraindication: known hypersensitivity to aripiprazole or any excipient.
Important warning: avoid use in elderly patients with dementiaârelated psychosis due to increased mortality risk.
Highârisk groups requiring extra monitoring include the elderly, pregnant or breastfeeding women (use specialist liaison), patients with severe hepatic or renal impairment, those with a seizure history, and people with cardiovascular disease.
Metabolic monitoring is advised for patients with diabetes or metabolic syndrome, and clinicians should be alert for EPS and signs consistent with neuroleptic malignant syndrome (NMS).
Lifestyle advice: avoid heavy alcohol, and counsel patients not to drive or operate machinery until they understand how aripiprazole affects them.
Pharmacy counselling checklist:
- Confirm allergy status and current medications.
- Advise on monitoring parameters: BP, fasting glucose, lipids, weight and EPS scales.
- Encourage Yellow Card reporting for suspected adverse drug reactions and record events in the NHS patient record.
Dosage guidelines (NHSârecommended regimens and adjustments)
What are standard dosing regimens and practical advice for missed doses?
| Indication | Typical dose | Max dose |
|---|---|---|
| Schizophrenia (Adult) | 10â15 mg/day | 30 mg/day |
| Bipolar Mania (Adult) | 15 mg/day | 30 mg/day |
| Adjunct Depression (Adult) | 2â5 mg/day (lowâdose start) | 15 mg/day |
| LAI (Maintena) | 400 mg monthly IM (300 mg alternative clinically) | 400 mg monthly |
Special populations: start lower and titrate slowly in the elderly, and seek specialist advice for severe hepatic or renal impairment.
LAI initiation: maintain a 14âday oral overlap after the first injection when using Abilify Maintena.
Missed dose advice for oral therapy: take as soon as remembered unless it is near the time for the next dose; do not double up.
Missed LAI window: contact the prescriber for an individualised plan rather than selfâadministering oral doses.
Interactions overview (food, drink, drug interactions and Yellow Card signals)
Which drugs and substances affect aripiprazole levels or safety?
Aripiprazole is metabolised mainly by CYP2D6 and CYP3A4.
Strong CYP2D6 or CYP3A4 inhibitors such as fluoxetine or some azole antifungals can increase aripiprazole exposure and may require dose review or monitoring.
Strong inducers such as carbamazepine may reduce aripiprazole concentrations and compromise efficacy unless dosing adjustments are made.
Concomitant alcohol, benzodiazepines or other sedatives can increase somnolence and fall risk; advise patients accordingly.
| Interacting agent | Effect | Pharmacist action |
|---|---|---|
| Fluoxetine / Paroxetine | Increase aripiprazole levels (CYP2D6 inhibition) | Consider dose adjustment; monitor for adverse effects |
| Carbamazepine | Decrease aripiprazole levels (CYP3A4 induction) | Monitor clinical response; liaise with prescriber |
| Benzodiazepines / Alcohol | Increased sedation and fall risk | Advise on avoidance and driving cautions |
Akathisia and extrapyramidal symptoms are among the commonly reported adverse effects; suspected side effects can be reported via the Yellow Card scheme.
Comparable medicines and prescribing preferences (NHS alternatives)
How does aripiprazole stack up against common NHS alternatives?
Common alternatives include risperidone, olanzapine, quetiapine, paliperidone and lurasidone.
Aripiprazole often becomes the drug of choice when minimising metabolic risk is a priority or when partial dopamine agonism is clinically desirable.
| Drug | Key benefit | Main adverse concern | LAI available? |
|---|---|---|---|
| Aripiprazole | Lower metabolic liability; partial agonist action | Akathisia, insomnia | Yes (Abilify Maintena) |
| Olanzapine | Strong antipsychotic efficacy | High weight gain and metabolic risk | Yes |
| Risperidone/Paliperidone | Effective, wellâstudied | Prolactin elevation, metabolic change | Yes |
Document the clinical rationale for antipsychotic selection in the NHS record and follow local Trust formulary guidance, particularly for LAI commissioning.
FAQ
Will aripiprazole make me gain weight?
Compared with some antipsychotics such as olanzapine, aripiprazole generally carries a lower risk of weight gain, but metabolic changes and weight increase can still occur; monitor weight, BMI and blood tests as directed.
Can I drink alcohol or drive on aripiprazole?
Avoid heavy alcohol while taking aripiprazole, and do not drive until you know how the medicine affects alertness and coordination.
What if I miss a dose or stop treatment?
If you miss an oral dose, take it when you remember unless it is nearly time for the next dose â do not double up; for a missed LAI appointment contact your prescriber promptly as plans vary by clinical team.
How will side effects be monitored?
NHS monitoring typically includes baseline weight/BMI, fasting glucose and lipids, with review at 4â12 weeks and regular followâup thereafter; report suspected adverse reactions via the Yellow Card scheme.
When to seek urgent help
- Severe restlessness or inability to sit still (possible severe akathisia).
- High fever, muscle rigidity, confused state or autonomic instability (seek urgent care for possible NMS).
- Breathing difficulties, fainting or chest pain.
Guidelines for proper use (UK pharmacist counselling and NHS portals)
What should pharmacists cover when counselling a patient starting aripiprazole?
- Confirm the licensed indication and whether the prescription is onâlabel or offâlabel and document consent where appropriate.
- Check for CYP2D6/CYP3A4 inhibitors or inducers in the medication list and advise on interaction risks.
- Explain dose, titration schedule and the need for a 14âday oral overlap when initiating Abilify Maintena.
- Counsel on common adverse effects (akathisia, insomnia, nausea) and provide practical coping strategies.
- Record counselling entries in the NHS patient record and arrange NHS portal followâup for blood tests and reviews.
Redâflag symptoms that require urgent escalation include signs suggestive of NMS, severe EPS, suicidal ideation, or marked sedation affecting breathing.
Provide printed NHS or RCPsych leaflets where possible and discuss electronic repeat prescriptions and community pharmacy delivery services for continuity.
Encourage Yellow Card reporting of suspected ADRs and follow local Trust ADR pathways for serious events.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9â21 days |
| Birmingham | England | 9â21 days |
| Manchester | England | 9â21 days |
| Glasgow | Scotland | 9â21 days |
| Leeds | England | 9â21 days |
| Sheffield | England | 9â21 days |
| Bristol | England | 9â21 days |
| Liverpool | England | 9â21 days |
| Edinburgh | Scotland | 9â21 days |
| Cardiff | Wales | 9â21 days |
| Belfast | Northern Ireland | 9â21 days |
| Newcastle Upon Tyne | England | 9â21 days |
| Nottingham | England | 9â21 days |
| Plymouth | England | 9â21 days |
